CMPX
Compass Therapeutics·NASDAQ
--
--(--)
--
--(--)
8.82 / 10
Outperform
Capital flow assessment yields 7.64/10, denoting robust fund flow characteristics. Strengths in Small, Medium, and Large trends confront pressures from overall, block, and Extra-large patterns, resulting in positive liquidity outlook. Analyst perspective reveals overwhelmingly bullish analyst consensus with strong conviction. Rating breakdown: Strong Buy(100.0%) from 1 analyst assessments, supported by 10.00 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-24
InstitutionGuggenheim
Times predicted5
Historical Win Rate100.0%
Is money flowing into or out of CMPX?
- CMPX holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 8.82/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
